LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) is sponsoring the inaugural Good Health: Mind, Body & Soul Summit, an invitation-only event scheduled for February 19 at Morehouse College in Atlanta. The Summit brings together leaders in health, culture, science, and community to advance health equity for Black men and families and is rooted in De La Soul's song "Good Health," written following the passing of founding member David Jolicoeur. Developed in collaboration with Blacksmith holdings, the program reflects De La Soul's evolution from musical pioneers to wellness advocates and will feature discussions spanning cancer, heart disease, mental health, addiction, sleep, relationships, and intergenerational wellness.
LIXTE said the Summit aligns with its mission as a clinical-stage pharmaceutical company advancing cancer care through its first-in-class oncology compound LB-100 and its European research subsidiary, LIORA, while creating a space to connect scientific innovation with communities most impacted by health disparities. The company's sponsorship represents a strategic intersection of pharmaceutical research and community health initiatives, particularly relevant given the documented health disparities affecting Black communities in areas including cancer outcomes, cardiovascular disease, and mental health access.
LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. LIXTE has demonstrated that its first-in-class lead clinical PP2A inhibitor, LB-100, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data available at https://www.lixte.com, LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer.
The company's lead compound, LB-100, is part of a pioneering effort in an entirely new field of cancer biology – activation lethality – that is advancing a new treatment paradigm. LIXTE's new approach is covered by a comprehensive patent portfolio. Proof-of-concept clinical trials are currently in progress for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer. The latest news and updates relating to LIXT are available in the company's newsroom at https://ibn.fm/LIXT.
This sponsorship matters because it represents a convergence of pharmaceutical innovation and community health equity efforts at a time when racial disparities in healthcare outcomes remain significant. By supporting this summit, LIXTE is not only advancing awareness of its cancer research but also positioning itself as a stakeholder in addressing broader health inequities. The implications extend beyond corporate social responsibility to potential long-term benefits for both the company's research pipeline and the communities it aims to serve, particularly as healthcare increasingly recognizes the importance of addressing social determinants of health alongside medical interventions.
